In the ongoing human effort to outmaneuver cancer's defenses, a Chinese clinical trial has offered a quietly significant finding: a two-drug combination targeting the HER2 protein from both inside and outside the cell achieved complete tumor elimination in 60% of women with advanced breast cancer before surgery. The neoPICD trial, conducted across seven centers in China, enrolled 108 evaluable patients and produced response rates that rival or exceed some current global standards. While the absence of a direct comparison group tempers certainty, the results invite a deeper question about wheth
The ASCO Post
· Jul 24, 2026
· health
· 4 min de leitura
High
Apuração: Verificado
Dual HER2-Targeted Combo Achieves 60% Pathologic Response in Advanced Breast Cancer
◉
Health & Medicine
9464 artigos relacionados
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% correspondência
Cancer vaccine shows striking tumor elimination in international trial
Malay Mail · 99% correspondência
Alzheimer's Drug Approvals Split Regulators on Benefits vs. Safety Tra…
News-Medical · 99% correspondência
Rogan podcast mentions of Vitamin A linked to surge in toxic measles '…
Nine.com.au · 99% correspondência
GLP-1 drugs show potential cancer benefits across multiple tumor types…
CNA Lifestyle · 99% correspondência
Cobertura Relacionada
CBS News · Sep 16
NBC Los Angeles news helicopter crashes in Chatsworth, killing 3
An NBC Los Angeles news helicopter crashed in Chatsworth on Tuesday evening, killing at least three people with two othe…
BBC News · Sep 16 LA news helicopter crashes while covering bus collision; 3 deadAn NBC Los Angeles news helicopter crashed in Chatsworth while covering a deadly bus collision, killing three people abo…
The Canberra Times · Sep 16 Three killed in helicopter crash near Los AngelesAt least three people died when a helicopter crashed in Chatsworth, suburban Los Angeles, near where emergency crews wer…
Inside Precision Medicine · Sep 16 AACR Report: FDA Approves 10 Targeted Cancer Therapies in 12 MonthsThe 2026 AACR Cancer Progress Report documents FDA approval of 10 new molecularly targeted cancer therapies and companio…
Viés e Enquadramento
⚖
Medical journal article presenting clinical trial results with factual reporting, minimal bias detected, though geographic focus and drug approval status warrant consideration.
Bias Direction
center
Confidence
MED
Objective clinical reporting with emphasis on efficacy metrics and mechanistic rationale. Comparative framing positions new combination against established standard (trastuzumab/pertuzumab) using response rate ranges.
high pathologic response rates
exceeding some standard treatments
substantial proportion of patients still do not achieve
Safety/toxicity profile comparison with standard regimens
Cost-effectiveness or accessibility considerations
Patient-reported outcomes or quality of life data
Perspectives from oncologists outside China
Limitations or potential criticisms of single-arm trial design
Long-term follow-up data or recurrence rates
Impacto Geopolítico
🌎
Chinese-developed HER2-targeted cancer drugs demonstrate superior efficacy, potentially reducing Western pharmaceutical dominance in oncology and signaling China's biotech advancement.
Escalation Risk
low
Confidence
MED
China
United States
Singapore
European Union
Asia-Pacific
China's development of inetetamab and pyrotinib represents a shift in pharmaceutical innovation from Western monopoly toward multi-polar biotech competition. Success in clinical trials strengthens China's position in global oncology markets and reduces dependence on U.S./EU drugs. This challenges Western pharmaceutical pricing power and regulatory influence, while positioning China as a credible innovator rather than solely a generic manufacturer.
Similar to China's advancement in solar panel and EV battery manufacturing—moving from imitation to innovation leadership in strategic sectors, now extending to high-value pharmaceuticals.
Lente Econômica
📈
Chinese dual HER2-targeted therapy achieves 60% pathologic response in breast cancer, potentially expanding treatment options and creating market opportunities in oncology therapeutics.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Oncology/Cancer Treatment
Medical Devices & Diagnostics
Healthcare Services
Healthcare Insurance
Patients with HER2-positive breast cancer may gain access to potentially more effective treatment options with higher response rates, though availability depends on regulatory approval and pricing. Improved outcomes could reduce long-term healthcare costs for some patients.
FDA approval pathway likely for inetetamab and pyrotinib in US markets; potential for accelerated review given superior efficacy data. May influence treatment guidelines and reimbursement policies. Could accelerate Chinese pharmaceutical innovation recognition globally and impact competitive dynamics in HER2-targeted therapy market.